XML 153 R46.htm IDEA: XBRL DOCUMENT
v3.23.3

Commitments and Contingencies (Details Narrative) - USD ($) |  |  |  |  | 6 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 19, 2022 | Mar. 19, 2022 | Feb. 15, 2022 | Nov. 27, 2018 | Aug. 15, 2018 | Jun. 30, 2023
Royalty Agreement [Member] |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Royalty percentage |  |  |  |  | 50.00% |
Sale of royalty percentage |  |  | 20.00% | 5.00% |  |
Development cost, percent |  | 50.00% |  |  |  |
Royalty Agreement [Member] | Chemia Corporation [Member] |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Royalty percentage |  |  |  |  | 50.00% | 50.00%
License Agreement [Member] |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Sale of royalty percentage |  | 5.50% |  |  |  |
Development cost, percent | 50.00% |  |  |  |  |
Development costs |  | $ 1,250,000 |  |  |  |
Global And Bio Life Sciences [Member] |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |
Sale of royalty percentage |  |  | 20.00% |  |  |

X
- Definition Development cost percent. + References No definition available. + Details
Name: | IMPB_DevelopmentCostPercent
Namespace Prefix: | IMPB_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty percentage. + References No definition available. + Details
Name: | IMPB_RoyaltyPercentage
Namespace Prefix: | IMPB_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sale of royalty percentage. + References No definition available. + Details
Name: | IMPB_SaleOfRoyaltyPercentage
Namespace Prefix: | IMPB_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 932 -SubTopic 235 -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482274/932-235-50-18 + Details
Name: | us-gaap_CostsIncurredDevelopmentCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=IMPB_RoyaltyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=IMPB_ChemiaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=IMPB_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=IMPB_GlobalAndBioLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |